QuidelOrtho Corporation (NASDAQ:QDEL) Receives Average Recommendation of “Reduce” from Analysts

Shares of QuidelOrtho Corporation (NASDAQ:QDEL) have earned a consensus rating of “Reduce” from the six analysts that are covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell recommendation and three have issued a hold recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $14.8750.

Several research analysts have recently weighed in on the stock. Wall Street Zen cut shares of QuidelOrtho from a “buy” rating to a “hold” rating in a report on Sunday, April 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of QuidelOrtho in a research report on Tuesday, April 21st. UBS Group reiterated a “neutral” rating and issued a $12.00 target price on shares of QuidelOrtho in a research report on Thursday, May 7th. Citigroup cut their target price on shares of QuidelOrtho from $30.00 to $13.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Finally, Zacks Research lowered shares of QuidelOrtho from a “hold” rating to a “strong sell” rating in a research report on Tuesday, February 17th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Global Retirement Partners LLC grew its position in QuidelOrtho by 3,691.7% in the fourth quarter. Global Retirement Partners LLC now owns 910 shares of the company’s stock worth $26,000 after acquiring an additional 886 shares in the last quarter. Camelot Portfolios LLC purchased a new position in QuidelOrtho in the fourth quarter worth $29,000. Hantz Financial Services Inc. grew its position in QuidelOrtho by 50.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock worth $31,000 after acquiring an additional 362 shares in the last quarter. Nisa Investment Advisors LLC grew its position in QuidelOrtho by 118.1% in the third quarter. Nisa Investment Advisors LLC now owns 1,280 shares of the company’s stock worth $38,000 after acquiring an additional 693 shares in the last quarter. Finally, Larson Financial Group LLC grew its position in QuidelOrtho by 322.2% in the third quarter. Larson Financial Group LLC now owns 1,330 shares of the company’s stock worth $39,000 after acquiring an additional 1,015 shares in the last quarter. 99.00% of the stock is currently owned by hedge funds and other institutional investors.

QuidelOrtho Trading Up 5.0%

QuidelOrtho stock opened at $11.38 on Friday. The stock has a market cap of $776.00 million, a P/E ratio of -0.64 and a beta of 0.75. QuidelOrtho has a fifty-two week low of $9.92 and a fifty-two week high of $35.58. The firm’s fifty day moving average price is $14.36 and its 200-day moving average price is $22.53. The company has a debt-to-equity ratio of 1.33, a quick ratio of 0.80 and a current ratio of 1.43.

QuidelOrtho (NASDAQ:QDEL) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.41). The firm had revenue of $619.80 million during the quarter, compared to the consensus estimate of $665.23 million. QuidelOrtho had a positive return on equity of 4.25% and a negative net margin of 45.57%.The company’s revenue for the quarter was down 10.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.74 EPS. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. Equities research analysts forecast that QuidelOrtho will post 1.83 earnings per share for the current fiscal year.

About QuidelOrtho

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.